ZHIFEI-BIOL(SZ:300122) Xin Lang Cai Jing·2025-11-18 01:26Core Viewpoint - The financial performance of Zhifei Biological is declining, with significant decreases in revenue and net profit, while the stock's financing and margin trading activities indicate a low level of investor confidence [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion yuan, a year-on-year decrease of 66.53% [2]. - The company experienced a net profit attributable to shareholders of -1.206 billion yuan, representing a year-on-year decrease of 156.10% [2]. - Cumulatively, since its A-share listing, Zhifei Biological has distributed a total of 7.318 billion yuan in dividends, with 3.194 billion yuan distributed over the past three years [2]. Group 2: Stock and Financing Activity - On November 17, Zhifei Biological's stock price fell by 1.30%, with a trading volume of 493 million yuan [1]. - The financing buy-in amount for Zhifei Biological on the same day was 50.144 million yuan, while the financing repayment was 55.099 million yuan, resulting in a net financing buy-in of -4.9549 million yuan [1]. - The total margin trading balance for Zhifei Biological as of November 17 was 1.406 billion yuan, with the financing balance accounting for 2.76% of the circulating market value, which is below the 30% percentile level over the past year [1]. Group 3: Shareholder Structure - As of November 10, the number of shareholders for Zhifei Biological was 133,100, an increase of 1.19% from the previous period [2]. - The average number of circulating shares per shareholder was 10,624 shares, a decrease of 1.17% from the previous period [2]. - Major institutional shareholders have reduced their holdings, with significant decreases noted among the top ten circulating shareholders [2].